Back to Studies

Syn-Ake

Dipeptide Diaminobutyroyl Benzylamide Diacetate, SYN®-AKE, Waglerin-1 mimic

Quick Stats

Studies 1

Trials 0

Overview Studies Clinical Trials

Score 3

2023 pubmed 10 citations

Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests.

Gok. Bahar B; Budama-Kilinc. Yasemin Y; Kecel-Gunduz. Serda S

View on DOI View Original Source

Key Findings

Syn‑Ake shows strong, stable binding to anti‑aging targets MMP‑13 and SIRT1 in docking and 50 ns molecular dynamics simulations.
The peptide exhibits dose‑dependent antioxidant activity in the DPPH radical‑scavenging assay.
Cytotoxicity (MTT) and genotoxicity (Ames) tests indicate a favorable safety profile at the tested concentrations.

Practical Outcomes

For DIY biohackers, Syn‑Ake looks promising as a topical anti‑aging ingredient, but there’s no human dosage or efficacy data yet. You could consider it for experimental skin‑care formulations, keeping doses low and monitoring for any irritation, while awaiting more robust in‑vivo evidence.

Summary

Researchers tested a lab-made peptide called Syn‑Ake and found it sticks well to proteins linked to aging (MMP‑13 and SIRT1), can neutralize free radicals in a test tube, and appears safe in basic cell‑toxicity and bacterial mutation assays. The work is all computer‑modeling and lab‑bench work, not human trials.

Abstract

The increase in the aging population worldwide has led scientists to turn to research to prevent the aging process. In this context, synthetic peptides emerge as candidate molecules for developing new anti-aging products. This study aims to investigate the possible interactions of Syn-Ake, a synthetic peptide, with matrix metalloproteinases (MMPs) and Sirtuin 1 (SIRT1), which are the targets of anti-aging activities with in silico approaches, and to determine the antioxidant activity, and safety profile of the peptide by in vitro methods such as cytotoxicity (MTT) and genotoxicity (Ames) tests. The molecular docking study showed that the docking score energy of MMP receptors was in the order of MMP-13 < MMP-8 < MMP-1. Syn-Ake peptide provided the lowest and the most stable binding to the SIRT1 receptor at -9.32 kcal/mol. Binding interaction and protein-ligand stability of Syn-Ake with MMPs and SIRT1 in a dynamic system were predicted by 50 ns molecular dynamic (MD) simulation studies. The MD results showed that the Syn-Ake peptide remained stable in the active site of MMP-13 and SIRT1 receptors during 50 ns simulations. In addition, the antioxidant activity of Syn-Ake was investigated using diphenyl-2-picril-hydrazine (DPPH) method since it is crucial to remove free radicals that are effective in skin aging. The results revealed the concentration-dependent increased DPPH radical scavenging activity of the peptide. Finally, the safety of the Syn-Ake was investigated, and the safe dose of the peptide was determined. In conclusion, in silico and in vitro analyses show that the Syn-Ake peptide may hold promise in anti-aging formulations with its high efficacy and safety profile.Communicated by Ramaswamy H. Sarma.

Study Information

Provider

pubmed

Year

2023

Date

2023-06-22T00:00:00.000Z

DOI

10.1080/07391102.2023.2223681

Citations

References